Form 8-K

8-K — STRYKER CORP

Accession: 0000310764-26-000025

Filed: 2026-04-30

Period: 2026-04-30

CIK: 0000310764

SIC: 3841 (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS)

Item: Results of Operations and Financial Condition

Item: Financial Statements and Exhibits

Documents

8-K — syk-20260430.htm (Primary)

EX-99.1 (sykex991earningsq12026.htm)

GRAPHIC (syk-20260430_g1.jpg)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K

8-K (Primary)

Filename: syk-20260430.htm · Sequence: 1

syk-20260430

false000031076400003107642026-04-302026-04-300000310764us-gaap:CommonStockMember2026-04-302026-04-300000310764syk:SeniorUnsecuredNotes2.125Due2027Member2026-04-302026-04-300000310764syk:SeniorUnsecuredNotes3.375Due2028Member2026-04-302026-04-300000310764syk:SeniorUnsecuredNotes0.750Due2029Member2026-04-302026-04-300000310764syk:SeniorUnsecuredNotes2.625Due2030Member2026-04-302026-04-300000310764syk:SeniorUnsecuredNotes1.000Due2031Member2026-04-302026-04-300000310764syk:SeniorUnsecuredNotes3.375Due2032Member2026-04-302026-04-300000310764syk:SeniorUnsecuredNotes3.625Due2036Member2026-04-302026-04-30

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): April 30, 2026

STRYKER CORPORATION

(Exact name of registrant as specified in its charter)

Michigan 001-13149 38-1239739

(State of incorporation) (Commission File Number) (I.R.S. Employer Identification No.)

1941 Stryker Way Portage, Michigan 49002

(Address of principal executive offices) (Zip Code)

(269) 385-2600

(Registrant’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class Trading Symbol(s) Name of each exchange on which registered

Common Stock, $.10 Par Value SYK New York Stock Exchange

2.125% Notes due 2027 SYK27 New York Stock Exchange

3.375% Notes due 2028 SYK28 New York Stock Exchange

0.750% Notes due 2029 SYK29 New York Stock Exchange

2.625% Notes due 2030 SYK30 New York Stock Exchange

1.000% Notes due 2031 SYK31 New York Stock Exchange

3.375% Notes due 2032 SYK32 New York Stock Exchange

3.625% Notes due 2036 SYK36 New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging Growth Company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

ITEM 2.02 RESULTS OF OPERATIONS AND FINANCIAL CONDITION

Stryker Corporation issued a press release on April 30, 2026 announcing its first quarter 2026 operating results. A copy of this press release is attached hereto as Exhibit 99.1.

The information furnished in this report, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS

(d) Exhibits

99.1

Stryker reports first quarter 2026 operating results, press release dated April 30, 2026

104 Cover Page Interactive Data File (the cover page XBRL tags are embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

STRYKER CORPORATION

(Registrant)

Date: April 30, 2026 /s/ PRESTON W. WELLS

Preston W. Wells

Vice President, Chief Financial Officer

EX-99.1

Filename: sykex991earningsq12026.htm · Sequence: 2

Document

Exhibit 99.1

STRYKER REPORTS FIRST QUARTER 2026 OPERATING RESULTS

Portage, Michigan - April 30, 2026 - Stryker (NYSE:SYK) reported operating results for the first quarter of 2026:

First Quarter Results

•Reported net sales increased 2.6% to $6.0 billion

•Organic net sales increased 2.4%

•Reported operating income margin of 15.5%

•Adjusted operating income margin(1) contracted 180 bps to 21.1%

•Reported EPS increased 14.2% to $1.93

•Adjusted EPS(1) decreased 8.5% to $2.60

First Quarter Net Sales Growth Overview

Reported Foreign Currency Exchange Constant Currency Acquisitions / Divestitures Organic

MedSurg and Neurotechnology 5.0 % 1.4 % 3.6 % 2.7 % 0.9 %

Orthopaedics 0.1 1.9 (1.8) (5.9) 4.1

Total 2.6 % 1.6 % 1.0 % (1.4) % 2.4 %

“I am pleased with our team’s ability to recover quickly from the cyber incident and continue delivering for our customers and their patients,” said Kevin A. Lobo, Chair and CEO. “We remain committed to meeting our full year guidance for organic sales growth and adjusted earnings per share as our underlying business momentum remains strong.”

In the first quarter 2026 Stryker announced a change in our organizational structure. Our new Ortho Tech business combines the orthopaedic instruments portfolio from our Instruments business with the Mako and enabling technologies portfolio from our Other Orthopaedics business. By bringing Mako, power tools, cutting accessories, enabling technologies and the teams behind these products together under one business, we are simplifying the customer experience and striving to increase our speed to market through focused innovation. Prior period segment information has been recast to reflect these changes and they will have no impact on our consolidated financial statements. On our Investor Relations website at investors.stryker.com, we have provided additional information on our segment quarterly revenues for 2023, 2024 and 2025 that reflects the change in our organizational structure and other changes as if they had been effective for the periods presented.

Sales Analysis

Consolidated net sales of $6.0 billion increased 2.6% in the quarter and 1.0% in constant currency. Organic net sales increased 2.4% in the quarter including 2.1% from increased unit volume and 0.3% from higher prices.

MedSurg and Neurotechnology net sales of $3.2 billion increased 5.0% in the quarter and 3.6% in constant currency. Organic net sales increased 0.9% in the quarter including 0.3% from increased unit volume and 0.6% from higher prices.

Orthopaedics net sales of $2.8 billion increased 0.1% in the quarter and decreased 1.8% in constant currency. Organic net sales increased 4.1% in the quarter from increased unit volume.

Earnings Analysis

Reported net earnings of $745 million increased 13.9% in the quarter. Reported net earnings per diluted share of $1.93 increased 14.2% in the quarter. Reported gross profit margin and reported operating income margin were 63.3% and 15.5% in the quarter. Reported net earnings include certain items, such as charges for acquisition and integration-related activities, the amortization of purchased intangible assets, structural optimization and other special charges, goodwill and other impairments, costs to comply with certain medical device regulations, recall-related matters, regulatory and legal matters and tax matters. Excluding the aforementioned items, adjusted gross profit margin(1) was 63.6% in the quarter, and adjusted operating income margin(1) was 21.1% in the quarter. Adjusted net earnings(1) of $1.0 billion decreased 8.5% in the quarter. Adjusted net earnings per diluted share(1) of $2.60 decreased 8.5% in the quarter.

2026 Outlook

We are maintaining our full year 2026 guidance of organic net sales growth(2) in the range of 8.0% to 9.5% and adjusted net earnings per diluted share(2) in the range of $14.90 to $15.10. Our sales guidance includes a modestly positive pricing impact. Additionally, foreign exchange is expected to have a slightly favorable impact on both sales and adjusted net earnings per diluted share(2) should rates hold near current levels.

(1) A reconciliation of the non-GAAP financial measures: adjusted gross profit margin, adjusted operating income and adjusted operating income margin, adjusted net earnings and adjusted net earnings per diluted share, to the most directly comparable GAAP measures: gross profit margin, operating income and operating income margin, net earnings and net earnings per diluted share, and other important information accompanies this press release.

(2) We are unable to present a quantitative reconciliation of our expected net sales growth to expected organic net sales growth as we are unable to predict with reasonable certainty and without unreasonable effort the impact and timing of acquisitions and divestitures and the impact of foreign currency exchange rates. We are unable to present a quantitative reconciliation of our expected net earnings per diluted share to expected adjusted net earnings per diluted share as we are unable to predict with reasonable certainty and without unreasonable effort the impact and timing of structural optimization and other special charges, acquisition-related expenses and the outcome of certain regulatory, legal and tax matters. The financial impact of these items is uncertain and is dependent on various factors, including timing, and could be material to our Consolidated Statements of Earnings.

Conference Call on Thursday, April 30, 2026

As previously announced, we will host a conference call on Thursday, April 30, 2026 at 4:30 p.m., Eastern Time, to discuss our operating results for the quarter ended March 31, 2026 and provide an operational update.

Please register for this conference call at: https://stryker-1q2026-earnings.open-exchange.net. After registering, a confirmation will be sent via email, including dial-in details and unique conference call access codes required for call entry. Registration is open throughout the live call. To ensure you are connected prior to the beginning of the call, we suggest registering a minimum of 15 minutes before the start of the call.

A simultaneous webcast of the call will be accessible via the Investor Relations page of our website at www.stryker.com. For those not planning to ask a question of management, we recommend listening via the webcast. Please allow 15 minutes to register, download and install any necessary software.

Following the conference call, a replay will be available on our website up to one year from the time of the earnings call.

Caution Concerning Forward-Looking Statements

This press release contains information that includes or is based on forward-looking statements within the meaning of the federal securities law that are subject to various risks and uncertainties that could cause our actual results to differ materially from those expressed or implied in such statements. Such risks and uncertainties include, but are not limited to: weakening of economic conditions, or the anticipation thereof, that could adversely affect the level of demand for our or Inari's products; geopolitical risks, including from tariffs and the potential for further changes in trade policies and international conflicts, which have led to and could continue to lead to, among other things, increased market volatility; pricing pressures generally, including cost-containment measures that have adversely affected and could in the future adversely affect the price of or demand for our or Inari’s products; changes in foreign currency exchange markets; legislative and regulatory actions; unanticipated issues arising in connection with clinical studies and otherwise that affect approval of new products, including Inari's products, by the United States Food and Drug Administration and foreign regulatory agencies; inflationary pressures; increased interest rates or interest rate volatility; supply chain disruptions; changes in labor markets; changes in coverage and reimbursement levels from third-party payors; changes in the competitive environment; breaches, failures or other disruptions of our or our vendors’ or customers’ information technology systems or products resulting from cyber-attack, data leakage, unauthorized access or theft, including the cybersecurity incident first reported on March 11, 2026; a significant increase in product liability claims; the ultimate total cost with respect to recall-related and other regulatory and quality matters; the impact of investigative and legal proceedings and compliance risks; resolution of tax audits; changes in tax laws and regulations; the impact of legislation to reform the healthcare system in the United States or other countries; costs to comply with medical device regulations; changes in financial markets; changes in our credit ratings; our ability to integrate and realize the anticipated benefits of acquisitions in full or at all or within the expected timeframes, including our acquisition of Inari; our ability to realize any anticipated cost savings; risks relating to climate change or other environmental, social and governance and sustainability related matters; the impact on our operations and financial results of any public health emergency and any related policies and actions by governments or other third parties; unexpected liabilities, costs, charges or expenses in connection with the acquisition of Inari; and the effects of the Inari transaction on the parties’ relationships with employees, customers, other business partners or governmental entities. Additional information concerning these and other factors is contained in our filings with the United States Securities and Exchange Commission, including our Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. We disclaim any intention or obligation to publicly update or revise any forward-looking statement to reflect any change in our expectations or in events, conditions or circumstances on which those expectations may be based, or that affect the likelihood that actual results will differ from those contained in the forward-looking statements, except to the extent required by law.

Stryker is a global leader in medical technologies and, together with our customers, we are driven to make healthcare better. We offer innovative products and services in MedSurg, Neurotechnology and Orthopaedics that help improve patient and healthcare outcomes. Alongside our customers around the world, we impact more than 150 million patients annually. More information is available at www.stryker.com.

For investor inquiries:

Jason Beach, Vice President, Finance and Investor Relations at 269-385-2600 or jason.beach@stryker.com

For media inquiries:

Kim Montagnino, Vice President, Chief Communications Officer at 269-385-2600 or kim.montagnino@stryker.com

STRYKER CORPORATION

For the Three Months March 31

(Unaudited - Millions of Dollars, Except Per Share Amounts)

CONSOLIDATED STATEMENTS OF EARNINGS

Three Months

2026 2025 % Change

Net sales $ 6,020 $ 5,866 2.6 %

Cost of sales 2,210 2,122 4.1

Gross profit $ 3,810 $ 3,744 1.8 %

% of sales 63.3 % 63.8 %

Research, development and engineering expenses 413 405 2.0

Selling, general and administrative expenses 2,281 2,300 (0.8)

Amortization of intangible assets 180 167 7.8

Goodwill and other impairments — 35 nm

Total operating expenses $ 2,874 $ 2,907 (1.1) %

Operating income $ 936 $ 837 11.8 %

% of sales 15.5 % 14.3 %

Other income (expense), net (86) (73) 17.8%

Earnings before income taxes $ 850 $ 764 11.3 %

Income taxes 105 110 (4.5)

Net earnings $ 745 $ 654 13.9 %

Net earnings per share of common stock:

Basic $ 1.95 $ 1.71 14.0 %

Diluted $ 1.93 $ 1.69 14.2 %

Weighted-average shares outstanding (in millions):

Basic 382.9 381.7

Diluted 386.5 386.4

CONDENSED CONSOLIDATED BALANCE SHEETS

March 31 December 31

2026 2025

Assets

Cash and cash equivalents $ 2,878 $ 4,011

Marketable securities 87 89

Accounts receivable, net 3,571 4,039

Inventories 5,419 5,310

Prepaid expenses and other current assets 1,383 1,306

Total current assets $ 13,338 $ 14,755

Property, plant and equipment, net 3,887 3,876

Goodwill and other intangibles, net 24,704 24,972

Noncurrent deferred income tax assets 1,193 1,098

Other noncurrent assets 3,169 3,143

Total assets $ 46,291 $ 47,844

Liabilities and shareholders' equity

Current liabilities $ 6,315 $ 7,794

Long-term debt, excluding current maturities 14,224 14,859

Income taxes 403 402

Other noncurrent liabilities 2,370 2,369

Shareholders' equity 22,979 22,420

Total liabilities and shareholders' equity $ 46,291 $ 47,844

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

Three Months

2026 2025

Operating activities

Net earnings $ 745 $ 654

Depreciation 120 105

Amortization of intangible assets 180 167

Changes in operating assets, liabilities, income taxes payable and other, net (464) (676)

Net cash provided by operating activities $ 581 $ 250

Investing activities

Acquisitions, net of cash acquired $ (22) $ (4,749)

Proceeds/(Purchases) of short-term investments — 750

Purchases of property, plant and equipment (166) (123)

Other investing, net 3 (14)

Net cash used in investing activities $ (185) $ (4,136)

Financing activities

Borrowings (payments) of debt, net $ (1,000) $ 2,979

Payments of dividends (337) (320)

Other financing, net (173) (125)

Net cash provided by (used in) financing activities $ (1,510) $ 2,534

Effect of exchange rate changes on cash and cash equivalents (19) 20

Change in cash and cash equivalents $ (1,133) $ (1,332)

STRYKER CORPORATION

For the Three Months March 31

(Unaudited - Millions of Dollars)

SALES GROWTH ANALYSIS

Three Months

Percentage Change

2026 2025 As Reported Constant

Currency

Geographic:

United States $ 4,476 $ 4,440 0.8 % 0.8 %

International 1,544 1,426 8.3 1.5

Total $ 6,020 $ 5,866 2.6 % 1.0 %

Segment:

MedSurg and Neurotechnology $ 3,207 $ 3,056 5.0 % 3.6 %

Orthopaedics 2,813 2,810 0.1 (1.8)

Total $ 6,020 $ 5,866 2.6 % 1.0 %

SUPPLEMENTAL SALES GROWTH ANALYSIS

Three Months

Percentage Change

United States International

2026 2025 As Reported Constant Currency As Reported As Reported Constant Currency

MedSurg and Neurotechnology:

Instruments $ 920 $ 838 9.9 % 8.7 % 9.1 % 14.0 % 7.0 %

Endoscopy 868 867 0.1 (1.0) (1.2) 6.0 —

Medical 902 945 (4.6) (5.6) (6.9) 8.3 1.1

Vascular 517 406 27.5 24.0 37.9 17.0 10.5

$ 3,207 $ 3,056 5.0 % 3.6 % 3.2 % 11.7 % 5.1 %

Orthopaedics:

Knees $ 670 $ 639 4.7 % 2.8 % 1.4 % 13.5 % 6.1 %

Hips 460 443 3.7 1.2 2.3 6.0 (0.3)

Trauma and Extremities 1,035 945 9.5 7.4 7.6 15.3 6.8

Ortho Tech 646 617 4.8 3.2 2.0 12.9 6.5

$ 2,811 $ 2,644 6.3 % 4.3 % 4.0 % 12.2 % 4.9 %

Spinal Implants 2 166 (98.9) (99.0) (100.0) (96.2) (96.6)

$ 2,813 $ 2,810 0.1 % (1.8) % (2.0) % 5.5 % (1.3) %

Total $ 6,020 $ 5,866 2.6 % 1.0 % 0.8 % 8.3 % 1.5 %

Note: In the first quarter 2026 we announced a change in our organizational structure. Our new Ortho Tech business combines the orthopaedic instruments portfolio (Orthopaedic Instruments) from Instruments with Other Orthopaedics. In addition, Neuro Cranial and the spine enabling technologies portfolio (Enabling Technologies) from Other Orthopaedics was combined with the remaining Instruments business to align with our internal reporting structure. Ortho Tech includes sales related to Orthopaedic Instruments of $489 and $484 and Other Orthopaedics of $157 and $133. Instruments includes sales related to Neuro Cranial of $606 and $563 and Enabling Technologies of $26 and $29 for the three months 2026 and 2025. We have reflected these changes in all historical periods presented.

SUPPLEMENTAL INFORMATION - RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES

We supplement the reporting of our financial information determined under accounting principles generally accepted in the United States (GAAP) with certain non-GAAP financial measures, including: percentage sales growth in constant currency; percentage organic sales growth; adjusted gross profit; adjusted selling, general and administrative expenses; adjusted research, development and engineering expenses; adjusted operating income; adjusted other income (expense), net; adjusted income taxes; adjusted effective income tax rate; adjusted net earnings; and adjusted net earnings per diluted share (Diluted EPS). We believe these non-GAAP financial measures provide meaningful information to assist investors and shareholders in understanding our financial results and assessing our prospects for future performance. Management believes percentage sales growth in constant currency and the other adjusted measures described above are important indicators of our operations because they exclude items that may not be indicative of or are unrelated to our core operating results and provide a baseline for analyzing trends in our underlying businesses. Management uses these non-GAAP financial measures for reviewing the operating results of reportable business segments and analyzing potential future business trends in connection with our budget process and bases certain management incentive compensation on these non-GAAP financial measures.

To measure percentage sales growth in constant currency, we remove the impact of changes in foreign currency exchange rates that affect the comparability and trend of sales. Percentage sales growth in constant currency is calculated by translating current and prior year results at the same foreign currency exchange rate. To measure percentage organic sales growth, we remove the impact of changes in foreign currency exchange rates, acquisitions and divestitures, which affect the comparability and trend of sales. Percentage organic sales growth is calculated by translating current year and prior year results at the same foreign currency exchange rates excluding the impact of acquisitions and divestitures. To measure earnings performance on a consistent and comparable basis, we exclude certain items that affect the comparability of operating results and the trend of earnings. The income tax effect of each adjustment was determined based on the tax effect of the jurisdiction in which the related pre-tax adjustment was recorded. These adjustments are irregular in timing and may not be indicative of our past and future performance.

Because non-GAAP financial measures are not standardized, it may not be possible to compare these financial measures with other companies' non-GAAP financial measures having the same or similar names. These adjusted financial measures should not be considered in isolation or as a substitute for reported sales growth, gross profit, selling, general and administrative expenses, research, development and engineering expenses, operating income, other income (expense), net, income taxes, effective income tax rate, net earnings and net earnings per diluted share, the most directly comparable GAAP financial measures. These non-GAAP financial measures are an additional way of viewing aspects of our operations that, when viewed with our GAAP results and the reconciliations to corresponding GAAP financial measures below, provide a more complete understanding of our business. We strongly encourage investors and shareholders to review our financial statements and publicly-filed reports in their entirety and not to rely on any single financial measure.

The following reconciles the non-GAAP financial measures discussed above with the most directly comparable GAAP financial measures. The weighted-average diluted shares outstanding used in the calculation of adjusted net earnings per diluted share are the same as those used in the calculation of reported net earnings per diluted share for the respective period.

STRYKER CORPORATION

For the Three Months March 31

(Unaudited - Millions of Dollars, Except Per Share Amounts)

Reconciliation of Non-GAAP Financial Measures to the Most Directly Comparable GAAP Financial Measures

Three Months 2026 Gross Profit Selling, General & Administrative Expenses Research, Development & Engineering Expenses Operating Income Other Income (Expense), Net Income Taxes Net Earnings Effective

Tax Rate Diluted EPS

Reported $ 3,810 $ 2,281 $ 413 $ 936 $ (86) $ 105 $ 745 12.4 % $ 1.93

Reported percent net sales 63.3 % 37.9 % 6.9 % 15.5 % (1.4) % nm 12.4 %

Acquisition and integration-related costs:

Inventory stepped-up to fair value — — — — — — — — —

Other acquisition and integration-related (a) 2 (13) (4) 19 — 4 15 0.1 0.04

Amortization of purchased intangible assets — — — 180 — 30 150 0.6 0.38

Structural optimization and other special charges (b) 14 (104) — 118 (11) 25 82 1.1 0.21

Goodwill and other impairments (c) — — — — — — — — —

Medical device regulations (d) — — (5) 5 — 1 4 — 0.01

Recall-related matters (e) 1 (9) — 10 — 2 8 0.1 0.02

Regulatory and legal matters (f) — (3) — 3 — 1 2 — 0.01

Tax matters (g) — — — — — 2 (2) 0.2 —

Adjusted $ 3,827 $ 2,152 $ 404 $ 1,271 $ (97) $ 170 $ 1,004 14.5 % $ 2.60

Adjusted percent net sales 63.6 % 35.8 % 6.7 % 21.1 % (1.6) % nm 16.7 %

Three Months 2025 Gross Profit Selling, General & Administrative Expenses Research, Development & Engineering Expenses Operating Income Other Income (Expense), Net Income Taxes Net Earnings Effective

Tax Rate Diluted EPS

Reported $ 3,744 $ 2,300 $ 405 $ 837 $ (73) $ 110 $ 654 14.4 % $ 1.69

Reported percent net sales 63.8 % 39.2 % 6.9 % 14.3 % (1.2) % nm 11.1 %

Acquisition and integration-related costs:

Inventory stepped-up to fair value 34 — — 34 — 8 26 0.5 0.07

Other acquisition and integration-related (a) 13 (171) (1) 185 — 6 179 (2.5) 0.47

Amortization of purchased intangible assets — — — 167 — 34 133 1.4 0.35

Structural optimization and other special charges (b) 22 (19) — 41 — 14 27 1.0 0.07

Goodwill and other impairments (c) — — — 35 — 9 26 0.7 0.06

Medical device regulations (d) 1 — (11) 12 — 3 9 0.1 0.02

Recall-related matters (e) 31 (2) — 33 — 8 25 0.5 0.06

Regulatory and legal matters (f) — — — — — 1 (1) — —

Tax matters (g) — — — — — (19) 19 (2.4) 0.05

Adjusted $ 3,845 $ 2,108 $ 393 $ 1,344 $ (73) $ 174 $ 1,097 13.7 % $ 2.84

Adjusted percent net sales 65.5 % 35.9 % 6.7 % 22.9 % (1.2) % nm 18.7 %

nm - not meaningful

(a) Charges represent certain acquisition and integration-related costs associated with acquisitions, including:

Three Months

2026 2025

Employee retention and workforce reductions $ 3 $ 16

Changes in the fair value of contingent consideration 3 (2)

Manufacturing integration costs 5 4

Stock compensation payments upon a change in control — 139

Other integration-related activities (e.g., deal costs and legal entity rationalization) 8 28

Adjustments to Operating Income $ 19 $ 185

Other income taxes related to acquisition and integration-related costs 4 6

Adjustments to Income Taxes $ 4 $ 6

Adjustments to Net Earnings $ 15 $ 179

(b) Structural optimization and other special charges represent the costs associated with:

Three Months

2026 2025

Employee retention and workforce reductions $ 7 $ 32

Closure/transfer of manufacturing and other facilities (e.g., site closure, contract termination and redundant employee costs) 5 5

Product line exits 2 3

Termination of sales relationships in certain countries 81 —

Other charges 23 1

Adjustments to Operating Income $ 118 $ 41

Adjustments to Other Income (Expense), Net $ (11) $ —

Adjustments to Income Taxes $ 25 $ 14

Adjustments to Net Earnings $ 82 $ 27

Three Months

2026 2025

Certain long-lived and intangible asset write-offs and impairments $ — $ 34

Product line exits (e.g., long-lived asset and specifically-identified intangible asset write-offs) — 1

Adjustments to Operating Income $ — $ 35

Adjustments to Income Taxes $ — $ 9

Adjustments to Net Earnings $ — $ 26

(d) Charges represent the costs specific to updating our quality system, product labeling, asset write-offs and product remanufacturing to comply with the medical device reporting regulations and other requirements of the new medical device regulations in the European Union.

(e) Charges represent changes in our best estimate of the probable loss, or the minimum of the range of probable losses when a best estimate within a range is not known, to resolve certain recall-related matters.

(f) Charges represent changes in our best estimate of the probable loss, or the minimum of the range of probable losses when a best estimate within a range is not known, to resolve certain regulatory or other legal matters and the amount of favorable awards from settlements.

(g) Benefits / (charges) represent the accounting impact of certain significant and discrete tax items, including:

Three Months

2026 2025

Adjustments related to the transfer of certain intellectual properties between tax jurisdictions $ (20) $ (47)

Other tax matters 22 28

Adjustments to Income Taxes $ 2 $ (19)

Adjustments to Other Income (Expense), Net $ — $ —

Adjustments to Net Earnings $ (2) $ 19

GRAPHIC

Filename: syk-20260430_g1.jpg · Sequence: 7

Binary file (46212 bytes)

Download syk-20260430_g1.jpg

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 20

v3.26.1

COVER PAGE

Apr. 30, 2026

Document Information [Line Items]

Document Type

8-K

Document Period End Date

Apr. 30, 2026

Entity Registrant Name

STRYKER CORP

Entity Incorporation, State or Country Code

Entity File Number

001-13149

Entity Tax Identification Number

38-1239739

Entity Address, Address Line One

1941 Stryker Way

Entity Address, City or Town

Portage,

Entity Address, State or Province

Entity Address, Postal Zip Code

49002

City Area Code

(269)

Local Phone Number

385-2600

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Entity Emerging Growth Company

false

Amendment Flag

false

Entity Central Index Key

0000310764

Common Stock, $.10 Par Value

Document Information [Line Items]

Title of 12(b) Security

Common Stock, $.10 Par Value

Trading Symbol

SYK

Security Exchange Name

NYSE

2.125% Notes due 2027

Document Information [Line Items]

Title of 12(b) Security

2.125% Notes due 2027

Trading Symbol

SYK27

Security Exchange Name

NYSE

3.375% Notes due 2028

Document Information [Line Items]

Title of 12(b) Security

3.375% Notes due 2028

Trading Symbol

SYK28

Security Exchange Name

NYSE

0.750% Notes due 2029

Document Information [Line Items]

Title of 12(b) Security

0.750% Notes due 2029

Trading Symbol

SYK29

Security Exchange Name

NYSE

2.625% Notes due 2030

Document Information [Line Items]

Title of 12(b) Security

2.625% Notes due 2030

Trading Symbol

SYK30

Security Exchange Name

NYSE

1.000% Notes due 2031

Document Information [Line Items]

Title of 12(b) Security

1.000% Notes due 2031

Trading Symbol

SYK31

Security Exchange Name

NYSE

3.375% Notes due 2032

Document Information [Line Items]

Title of 12(b) Security

3.375% Notes due 2032

Trading Symbol

SYK32

Security Exchange Name

NYSE

3.625% Notes due 2036

Document Information [Line Items]

Title of 12(b) Security

3.625% Notes due 2036

Trading Symbol

SYK36

Security Exchange Name

NYSE

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:

dei_DocumentInformationLineItems

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Details

Name:

us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember

Namespace Prefix:

Data Type:

Balance Type:

Period Type:

- Details

Name:

us-gaap_StatementClassOfStockAxis=syk_SeniorUnsecuredNotes2.125Due2027Member

Namespace Prefix:

Data Type:

Balance Type:

Period Type:

- Details

Name:

us-gaap_StatementClassOfStockAxis=syk_SeniorUnsecuredNotes3.375Due2028Member

Namespace Prefix:

Data Type:

Balance Type:

Period Type:

- Details

Name:

us-gaap_StatementClassOfStockAxis=syk_SeniorUnsecuredNotes0.750Due2029Member

Namespace Prefix:

Data Type:

Balance Type:

Period Type:

- Details

Name:

us-gaap_StatementClassOfStockAxis=syk_SeniorUnsecuredNotes2.625Due2030Member

Namespace Prefix:

Data Type:

Balance Type:

Period Type:

- Details

Name:

us-gaap_StatementClassOfStockAxis=syk_SeniorUnsecuredNotes1.000Due2031Member

Namespace Prefix:

Data Type:

Balance Type:

Period Type:

- Details

Name:

us-gaap_StatementClassOfStockAxis=syk_SeniorUnsecuredNotes3.375Due2032Member

Namespace Prefix:

Data Type:

Balance Type:

Period Type:

- Details

Name:

us-gaap_StatementClassOfStockAxis=syk_SeniorUnsecuredNotes3.625Due2036Member

Namespace Prefix:

Data Type:

Balance Type:

Period Type: